published meta-analysis   sensitivity analysis   studies

anti-inflammatory therapies in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsLopes MIF, 2020 1.06 [0.02; 56.61] 1.06[0.02; 56.61]Lopes MIF, 202010%35NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-06 00:51 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615 - roots T: 290